Efficacy and Safety of ES16001 in Patients With COVID-19

Summary

This is phase II/III, randomized, parallel-group, double-blind, placebo-controlled study. Patients must be at least 19 years of age (or according to the legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcription polymerase chain reaction (RT-PCR) analysis of rhinopharynx samples. RT-PCR analysis of rhinopharynx samples must be \<4 days old prior to the study enrolment

Timeline

Start

2021-07-05

Primary completion

2023-12-31

Completion

2023-12-31

Drugs

Indications